Selegiline improves excessive daytime sleepiness in Parkinson’s disease: an open-label observational study

Jinru Zhang1, Juping Chen2, Jia Li3, Jian Li4, Hong Miao2, Xiangyang Zhu5, Meng Meng5, Yang Han6, Jing Chen1, Xiaoyu Cheng5, Kangping Xiong5, Hong Jin1, Weifeng Luo1, Chengjie Mao1, Chunfeng Liu5

1Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China; 2Department of Neurology, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu, Jiangsu 215516, China; 3Department of Neurology, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China; 4Department of Neurology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China; 5Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215123, China.

To the Editor: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and sleep disturbance is a major disabling non-motor symptom.[1] Excessive daytime sleepiness (EDS) is defined as inappropriate and undesirable sleepiness during waking hours, which may occur during activities such as talking or driving. In PD patients, EDS increased the risk of accidents and resulted in a poor quality of life.[2]

Selegiline is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor, which improves motor symptoms and posture and gait in PD compared to placebos in double-blind placebo-controlled studies.[3,4] In patients with sleepiness, selegiline alleviates the symptoms of narcolepsy by increasing alertness.[5] Since Levodopa and dopamine agonists have little effects on EDS, we conducted an open-label clinical trial to determine whether selegiline would alleviate EDS in PD patients. We evaluated the effects of selegiline on daytime sleepiness, nighttime sleep quality, and quality of life. Referring to the adverse effects of selegiline, we studied the incidence of motor fluctuation and dyskinesia in our study.

This open-label observational study was conducted at the Department of Neurology of the Second Affiliated Hospital of Soochow University, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Second Affiliated Hospital of Nantong University, and JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine. This clinical trial was registered at http://register.clinicaltrials.gov (NCT04870372). We focused on the observation of the efficacy of selegiline in PD patients with EDS in the real world.

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University (JD-LK-2019-103-02). All subjects provided informed written consent before participating in the study. For every patient included, the written informed consent previously signed to allow the use of clinical data for research purposes was retrieved. Data were saved in a pseudonymized way and were processed according to local legal conditions.

This was a multicenter, 8-week, open-label observational study of PD patients with daytime sleepiness (Epworth Sleepiness Scale [ESS] score > 7). The study consisted of two clinic visits at baseline and Week 8, and one telephone checkup at Week 3. From the day after the baseline visit, selegiline was initiated with 5 mg once daily for the first week, and the dosage of selegiline was increased to 10 mg per day for the third to the eighth weeks. Other antiparkinsonian drugs continued unchanged during the eight weeks. Changes from baseline to Week 3 and Week 8 in ESS, Parkinson’s Disease Sleep Scale (PDSS), and Parkinson’s Disease Quality of Life Questionnaire 39 (PDQ-39) assessments were analyzed using mixed-effect models (repeated quantitative data, and abnormal distribution). In our mixed-effect model, the scores of ESS, PDSS, and PDQ-39 were dependent variables; follow-up duration was fixed effect factor. Paired chi-squared tests were used to assess the change in the percentage of patients with motor fluctuation and dyskinesia.

One hundred and forty-one subjects were enrolled in the study, among which, 121 completed the study, and

Jinru Zhang and Juping Chen contributed equally to this work.

Correspondence to: Chengjie Mao, Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, 1055 Sanxiong Road, Suzhou, Jiangsu 215004, China; E-Mail: drchengjiemao@163.com

Xiaoyu Cheng, Kangping Xiong, Hong Jin, Weifeng Luo, Chunfeng Liu. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University (JD-LK-2019-103-02). All subjects provided informed written consent before participating in the study. For every patient included, the written informed consent previously signed to allow the use of clinical data for research purposes was retrieved. Data were saved in a pseudonymized way and were processed according to local legal conditions.

This was a multicenter, 8-week, open-label observational study of PD patients with daytime sleepiness (Epworth Sleepiness Scale [ESS] score > 7). The study consisted of two clinic visits at baseline and Week 8, and one telephone checkup at Week 3. From the day after the baseline visit, selegiline was initiated with 5 mg once daily for the first week, and the dosage of selegiline was increased to 10 mg per day for the third to the eighth weeks. Other antiparkinsonian drugs continued unchanged during the eight weeks. Changes from baseline to Week 3 and Week 8 in ESS, Parkinson’s Disease Sleep Scale (PDSS), and Parkinson’s Disease Quality of Life Questionnaire 39 (PDQ-39) assessments were analyzed using mixed-effect models (repeated quantitative data, and abnormal distribution). In our mixed-effect model, the scores of ESS, PDSS, and PDQ-39 were dependent variables; follow-up duration was fixed effect factor. Paired chi-squared tests were used to assess the change in the percentage of patients with motor fluctuation and dyskinesia.

One hundred and forty-one subjects were enrolled in the study, among which, 121 completed the study, and

Jinru Zhang and Juping Chen contributed equally to this work.

Correspondence to: Chengjie Mao, Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, 1055 Sanxiong Road, Suzhou, Jiangsu 215004, China; E-Mail: drchengjiemao@163.com

Dr. Chunfeng Liu, Jiangsu Key Laboratory of Neuropsychiatric Diseases, Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215123, China; E-Mail: fuchunfeng@suda.edu.cn

Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2022;135(14)
and daytime dozing) were analyzed. All eight factors – nocturia, nocturnal motor symptoms, sleep refreshment, insomnia, nocturnal restlessness, nocturnal psychosis, quality of nighttime sleep, sleep onset and maintenance – were assessed. This included 39 items assessing eight aspects of quality of life in PD patients: mobility, activities of daily living, emotional well being, stigma, social support, cognition, communication, and bodily discomfort.

The total PDSS scores improved significantly after selegiline treatment (P < 0.05). All eight factors improved after selegiline treatment (P < 0.05).

The PDQ-39 scores at baseline and after 8 weeks of treatment were assessed [Table 1]. This included 39 items assessing eight aspects of quality of life in PD patients: mobility, activities of daily living, emotional well being, stigma, social support, cognition, communication, and bodily discomfort. The total scores for ESS, PDSS, and PDQ-39 improved significantly after selegiline treatment [Supplementary Figure 1, http://links.lww.com/CM9/B153]. The percentage of patients with motor fluctuations decreased significantly after 8 weeks of treatment (P = 0.022). The severity of motor fluctuation also improved (P = 0.037). However, there was no difference in the percentage of patients with dyskinesia or its severity improvement before and after treatment [Supplementary Table 1, http://links.lww.com/CM9/B153].

Patients with EDS showed significant improvements after selegiline treatment. There are three possible causes of daytime sleepiness. First, pathophysiological alterations in the mechanisms that regulate sleep and wakefulness may result in EDS. In the brainstem, the noradrenergic locus coeruleus, the noradrenergic dorsal motor nucleus of the vagus nerve, the serotonergic dorsal raphe nucleus, the histaminergic tuberomammillary nucleus, and the dopaminergic areas related to the arousal system controls all showed degeneration in PD patients. Second, dopaminergic therapies may cause EDS. Dopamine agonists were reported to cause somnolence as a significant adverse effect, and PD patients who took a dopamine agonist were more likely to have somnolence than those who did not. Third, poor nocturnal sleep is also correlated with EDS. Some sleep disorders such as restless legs syndrome (RLS), periodic limb movement disorder, and rapid eye movement sleep behavior disorder (RBS) may lead to sleep fragmentation, which in turn results in EDS.

MAO-B is a commonly used inhibitor in the treatment of PD; however, there have been no studies on the use of selegiline to treat EDS in PD patients. Selegiline caused a subjective increase in alertness for 4 to 8 h in 21 subjects.

---

**Table 1: General information and changes in ESS, PDSS, and PDQ-39 scores of Parkinson’s disease patients with excessive daytime sleepiness at baseline and after 3 and 8 weeks of treatment (n = 121).**

| Items                        | Baseline | Week 3      | Week 8      | P values |
|------------------------------|----------|-------------|-------------|----------|
| LEDD (mg)                    | 375 (300–450) | 425 (350–500) | 475 (400–550) | –        |
| Motor fluctuation, n (%)     | 50 (41.3)  | –           | 42 (34.7)   | 0.022    |
| Dyskinesia, n (%)            | 8 (6.6)   | –           | 8 (6.6)     | 1.000    |
| ESS score                    | 11 (8–13)  | 9 (7–11)    | 8 (6–10)    | <0.001   |
| PDSS total score             | 112 (94–120) | 119 (106–129) | 123 (110–131) | <0.001   |
| Overall quality of nighttime sleep | 7 (6–8) | 7 (6–9) | 8 (6–9) | <0.001   |
| Sleep onset and maintenance insomnia | 16 (12–18) | 17 (14–19) | 17 (15–19) | <0.001   |
| Nocturnal restlessness       | 16 (13–17) | 16 (13–18) | 16 (13–19) | <0.001   |
| Nocturnal psychosis          | 16 (13–19) | 17 (14–19) | 17 (14–19) | 0.001    |
| Nocturia                     | 15 (13–18) | 17 (14–19) | 17 (15–19) | <0.001   |
| Nocturnal motor symptoms     | 33 (29–35) | 33 (30–36) | 34 (31–37) | <0.001   |
| Sleep refreshment            | 8 (6–9)   | 9 (7–10)   | 9 (8–10)   | 0.007    |
| Daytime dozing               | 4 (3–6)   | 6 (4–8)    | 7 (4–8)    | <0.001   |
| PDQ-39 scores                | 45 (19–54) | –          | 23 (10–45) | <0.001   |
| Mobility                     | 10 (3–19)  | –          | 7 (2–15)   | 0.006    |
| Activities of daily living   | 7 (2–11)  | –          | 5 (2–9)    | <0.001   |
| Emotional well being         | 5 (2–10)  | –          | 4 (2–8)    | <0.001   |
| Stigma                       | 1 (0–6)   | –          | 1 (0–4)    | <0.001   |
| Social support               | 0 (0–1)   | –          | 0 (0–1)    | 0.130    |
| Cognition                    | 7 (3–8)   | –          | 5 (2–7)    | <0.001   |
| Communication                | 2 (0–3)   | –          | 1 (0–3)    | <0.001   |
| Bodily discomfort            | 3 (1–4)   | –          | 3 (1–4)    | <0.001   |

Data are presented as median (interquartile range) or numbers (%). *P < 0.05. ESS: Epworth Sleepiness Scale; LEDD: Levodopa-equivalent daily dose; PD: Parkinson’s disease; PDQ-39: Parkinson’s Disease Quality of Life Questionnaire 39; PDSS: Parkinson’s Disease Sleep Scale; N: Not available.
with narcoleptic syndrome after 4 weeks of treatment.\textsuperscript{5,13} Selegiline is mainly metabolized into amphetamine and methylamphetamine through the liver,\textsuperscript{13} which may increase alertness in PD patients. Selegiline has been shown to improve motor symptoms, but other effects were not investigated. Since EDS in patients with PD does not typically respond to dopaminergic therapy, selegiline may be effective in treating this condition. This study is important because it provides new information on the treatment of daytime sleepiness in PD patients.

This study has some limitations: first, the control group is not included in this study; thus, the possibility of placebo effects cannot be excluded. The main reason is that it is difficult to control the control group and lack of consideration in the design status. Further replications with the control group are needed to verify the efficacy and safety of selegiline for daytime sleepiness in PD patients. Second, we assessed EDS and sleep quality by ESS and PDSS, not by polysomnography. ESS correlates with the results of multiple sleep latency tests and overnight polysomnography.\textsuperscript{14} Hence, we believe that ESS is an objective, easily administered measure of EDS. Finally, since selegiline has achieved good results in improving motor symptoms for PD patients,\textsuperscript{3,4} we did not assess the motor symptoms, including Unified Parkinson Disease Rating Scale Part III; therefore, the sleep benefits may have resulted from improved motor symptoms.

In this study, we found that selegiline might be an effective add-on treatment for EDS syndrome in PD patients. Further research is needed to determine the safety and efficacy of selegiline for EDS in PD.

Funding

This work was supported by grants from Jiangsu Provincial Key R&D Program (BE2018658), Suzhou Science and Technology Development Plan (Minsheng Science and Technology) (SKJY2021089); Discipline Construction Program of the Second Affiliated Hospital of Soochow University (XTKJ-XK202001); and Gusu Health Talents Plan (GSWS2020035, GSWS2019041).

Conflicts of interest

None.

References

1. Cao XY, Zhang JR, Shen Y, Mao CJ, Shen YB, Cao YL, et al. Fatigue correlates with sleep disturbances in Parkinson disease. Chin Med J 2020;134:668–674. doi: 10.1097/CMJ.0000000000002103.
2. Fabbri G, Barbanti P, Aurilia C, Pauluzzi C, Vanacore N, Meco G. Excessive daytime somnolence in Parkinson’s disease. Follow-up after 1 year of treatment. Neurol Sci 2003;24:178–179. doi: 10.1007/s10072-003-0118-y.
3. Heinonen EH, Rinne UK, Tommisse J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand Suppl 1989;126:113–118. doi: 10.1111/j.1600-0404.1989.tb01790.x.
4. Mizuno Y, Hatton N, Kondo T, Nomoto M, Oyagasa H, Takahashi R, et al. A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease. Clin Neuropharmacol 2017;40:201–207. doi: 10.1097/WNF.0000000000000259.
5. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmo T. Selegiline in the treatment of narcolepsy. Neurology 1994;44:2095–2101. doi: 10.1212/wnl.44.11.2095.
6. Chaudhuri KR, Pal S, DiMarco A, Whetly-Smith C, Bridgeman K, Mathew R, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson disease. J Neurol Neurosurg Psychiatry 2002;73:629–635. doi: 10.1136/jnnp.73.6.629.
7. Derck EE, Yaliman A, Kuru-Colaka T, Çakmak A, Razak Özdinçler A, Radil Demirbaş S. Turkish version study of “Parkinson’s Disease Quality of Life Questionnaire” (PDQL). Noro Psikiyatr Ars 2015;52:128–132. doi: 10.5152/npa.2015.7359.
8. Ongun N. Does nutritional status affect Parkinson’s disease features and quality of life? PLoS One 2018;13:e0205100. doi: 10.1371/journal.pone.0205100.
9. Bliverse DL, Trottin LM, Juncoos JJ, Factor SA, Freeman A, Rye DB. Daytime REM sleep in Parkinson’s disease. Parkinsonism Relat Disord 2015;21:91–103. doi: 10.1016/j.parkreldis.2015.08.003.
10. Olano CW, Chapin AH, Roh T. Waking up to sleep episodes in Parkinson’s disease. Mov Disord 2000;15:212–215. doi: 10.1002/1531-8257(200003)15:2<212::AID-MDS102>3.0.CO;2-6.
11. Ondo WG, Dat Vuong K, Khan H, Atassi P, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001;57:1392–1396. doi: 10.1212/WNL.57.8.1392.
12. Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Breffel-Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006;13:209–214. doi: 10.1111/j.1468-1331.2006.01262.x.
13. Roselaar SE, Langdon N, Lack CB, Jenner P, Parkes JD. Selegiline in narcolepsy. Sleep 1987;10:491–495. doi: 10.1093/sleep/10.5.491.
14. Bargiotas P, Lachenmayer ML, Schreier DR, Mathis J, Bassetti CL. Sleepiness and sleepiness perception in patients with Parkinson’s disease: a clinical and electrophysiologic study. Sleep 2009;32:zsz004. doi: 10.1093/sleep/zsz004.

How to cite this article: Zhang J, Chen J, Li J, Li J, Miao H, Zhu X, Meng M, Han Y, Chen J, Cheng X, Xiong K, Jin H, Luo W, Mao C, Liu C. Selegiline improves excessive daytime sleepiness in Parkinson’s disease: an open-label observational study. Chin Med J 2022;135:1762–1764. doi: 10.1097/CMJ.0000000000002308.